Board of Directors

The members of the Board of Directors comprise a group of professionally skilled business people representing a diversity and experience within animal health and life sciences, key competence areas for vaccine development. Current members are:
Styrelseordförande
Rune Bergman

DVM, PhD, Chairman of the board, Intervacc and CEO, Nordvacc Läkemedel AB.
Not independent of
The company and its executives.

Not independent of
major shareholders.

Kenneth Janzon

Laboratory engineer, microbiology. QA and CTO, Nordvacc Läkemedel AB.
Not independent of
The company and its executives.

Not independent of
major shareholders.

Jan-Ingmar Flock
Jan-Ingmar Flock

CEO, Intervacc. Professor at the Karolinska Institute, department of Microbiology, Tumor and Cell Biology.
Not independent of
The company and its executives.

Independent of
major shareholders.

Bengt Guss
Bengt Guss

Professor at the Swedish University of Agricultural Sciences, Department of Biomedical Sciences and Veterinary Public Health.
Independent of
The company and its executives.

Independent of
major shareholders.

Olle Kämpe
Olle Kämpe

Professor, Clin. endocrinology at the Karolinska Institute. Fellow of the Royal Swedish Academy of Sciences, member of the Nobel Assembly.
Independent of
The company and its executives.

Not independent of
major shareholders.

Alexander Kotsinas
Alexander Kotsinas

M.Sc physics and B.Sc Economy, representing Nxt2b.
Independent of
The company and its executives.

Not independent of
major shareholders.

Stefan Ståhl
Stefan Ståhl

Professor at the Royal Institute of Technology, department of molecular biotechology.
Independent of
The company and its executives.

Independent of
major shareholders.